Thinly traded nano cap Anixa Biosciences (NASDAQ:ANIX) is up 18% premarket on increased volume in reaction to its announcement that it and partner OntoChem GmbH have synthesized four compounds for the potential treatment of COVID-19.
Animal studies are next up. If successful, in-human trials will follow.
https://seekingalpha.com/news/3578993-anixa-rallies-on-development-of-four-covidminus-19-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.